Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00099216 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia
A Phase 3 study of Vascular Dementia, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 708
- Enrollment target
- 20
- Study locations
NCT00099216: Completed Phase 3 study of Vascular Dementia, sponsored by Novartis Pharmaceuticals.
NCT00099216 is a Phase 3 study of Vascular Dementia that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 708 participants, below the 1,127-participant average among 10 other Vascular Dementia trials with a reported enrollment target (37% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00099216, a Phase 3 study of Vascular Dementia, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 708 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this research study is to evaluate the effectiveness, tolerability and safety of rivastigmine capsules in males and females between the ages of 50 and 85 years old with probable vascular dementia.
Conditions Studied
Interventions
- DRUG Rivastigmine
Study Locations (20)
Florida
- - Boynton Beach
- - Miami Beach
- - Port Charlotte
Other
- - Graz
- - Linz
- - Vienna
California
- - Irvine
- - San Francisco
Pennsylvania
- - Allentown
- - Greensburg
Texas
- - Austin
- - Houston
Indiana
- - Indianapolis
Iowa
- - Des Moines
Missouri
- - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 708 participants |
| Start Date | 2001-08 |
| Est. Completion | 2005-11 |
| Phase | Phase 3 |
What the finished NCT00099216 record still lists
NCT00099216 is an interventional study that assigns participants to a tested intervention. The registered 708 participants enrollment target is mid-sized for trials with a published cap, below the 1,127-participant average among 10 other Vascular Dementia trials with a reported enrollment target (37% lower).
The record links to 1 condition, with Vascular Dementia appearing as the primary indexed condition, and to 1 intervention - of which Rivastigmine is the first listed.
NCT00099216 names 20 study sites across 13 states, led by Florida, Other, California.
Frequently Asked Questions
What is clinical trial NCT00099216 about?
NCT00099216 is a clinical study titled "Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia". The goal of this research study is to evaluate the effectiveness, tolerability and safety of rivastigmine capsules in males and females between the ages of 50 and 85 years old with probable vascular dementia.
What is the current status of trial NCT00099216?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 708 participants. The study started on 2001-08. Estimated completion is 2005-11.
What conditions does trial NCT00099216 study?
This clinical trial studies the following conditions: Vascular Dementia.
What interventions are being tested in trial NCT00099216?
The interventions under investigation include: Rivastigmine (DRUG).
Who is sponsoring clinical trial NCT00099216?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00099216 being conducted?
This trial has 20 study locations across California, Florida, Indiana, Iowa, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vascular Dementia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00099216's enrollment target sits among peer trials
708 2nd of 10 the highest of 10 other Vascular Dementia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Vascular Dementia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Longitudinal Cognitive Assessment by BoCA
RECRUITING
-
Pulsed Electromagnetic Field Treatment With Dementia Patients
RECRUITING · NA
-
Cognitive and Vascular Functioning Following TBI
RECRUITING
-
The BRAIN App (Phase 2 SBIR)
RECRUITING · NA
-
A Study That Collects Participant Data and Biospecimens to Analyze Pathogenic Exosomes That Mediate Increased Vascular Dementia Risk in Individuals With Herpes Zoster.
RECRUITING
-
Florida Cerebrovascular Disease Biorepository and Genomics Center
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06179160 · 710 participants · Phase 1
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- NCT06235697 · 710 participants · Phase 3
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
- NCT06470867 · 710 participants · NA
Randomized Controlled Effectiveness Trial of VA S.A.V.E.
- NCT07022483 · 710 participants · Phase 3
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia